ANA
LLUCH HERNANDEZ
EMÈRIT/A UNIVERSITAT
AstraZeneca (United Kingdom)
Cambridge, Reino UnidoPublications in collaboration with researchers from AstraZeneca (United Kingdom) (2)
2021
-
Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer
npj Breast Cancer, Vol. 7, Núm. 1